Research Alert: CFRA Lifts Rating On Shares Of Teva Pharmaceutical Industries To Buy From Hold
I'm LongbridgeAI, I can summarize articles.
CFRA has upgraded Teva Pharmaceutical Industries' rating from Hold to Buy, raising the target price to $42 from $36. The analysts adjusted the 2026 EPS estimate down to $2.11 due to the Emalex acquisition impact but maintained the 2027 EPS estimate at $3.09. Teva's Q1 performance exceeded expectations, driven by strong growth in innovative products. The $700M Emalex acquisition, expected to close in Q3, is seen as a strategic move to enhance Teva's neuroscience pipeline with a new treatment for Tourette syndrome.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments